EA201890130A1 - Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер - Google Patents
Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьерInfo
- Publication number
- EA201890130A1 EA201890130A1 EA201890130A EA201890130A EA201890130A1 EA 201890130 A1 EA201890130 A1 EA 201890130A1 EA 201890130 A EA201890130 A EA 201890130A EA 201890130 A EA201890130 A EA 201890130A EA 201890130 A1 EA201890130 A1 EA 201890130A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibody
- transferrin receptor
- human transferrin
- compounds
- penetrating
- Prior art date
Links
- 102000007238 Transferrin Receptors Human genes 0.000 title abstract 3
- 210000001218 blood-brain barrier Anatomy 0.000 title abstract 3
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 title abstract 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 title abstract 2
- 230000000149 penetrating effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000008499 blood brain barrier function Effects 0.000 abstract 2
- 108010033576 Transferrin Receptors Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000001766 physiological effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/02—Thioester hydrolases (3.1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01076—L-Iduronidase (3.2.1.76)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
- C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
- C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
Abstract
Раскрыты средства для того, чтобы превращать соединения, обладающие физиологической или фармакологической активностью и неспособные проходить через гематоэнцефалический барьер, в форму, которая позволяет им проходить через гематоэнцефалический барьер, и соединения, превращенные таким образом. Средством является антитело к рецептору трансферрина человека, и превращенными соединениями являются молекулярные конъюгаты между физиологически активным белком или фармакологически активными низкомолекулярными соединениями и антителом к рецептору трансферрина человека.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015144379 | 2015-06-24 | ||
PCT/JP2016/068738 WO2016208695A1 (ja) | 2015-06-24 | 2016-06-24 | 血液脳関門を通過する抗ヒトトランスフェリン受容体抗体 |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201890130A1 true EA201890130A1 (ru) | 2018-05-31 |
EA039366B1 EA039366B1 (ru) | 2022-01-19 |
Family
ID=57585554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201890130A EA039366B1 (ru) | 2015-06-24 | 2016-06-24 | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер |
Country Status (20)
Country | Link |
---|---|
US (2) | US11248045B2 (ru) |
EP (1) | EP3315606A4 (ru) |
JP (5) | JP6328851B2 (ru) |
KR (1) | KR20180020277A (ru) |
CN (2) | CN114409783A (ru) |
AU (2) | AU2016283343B2 (ru) |
BR (1) | BR112017027965A2 (ru) |
CA (1) | CA2990785A1 (ru) |
CL (2) | CL2017003351A1 (ru) |
CO (1) | CO2018000235A2 (ru) |
EA (1) | EA039366B1 (ru) |
HK (2) | HK1245328A1 (ru) |
IL (2) | IL256497B (ru) |
MX (1) | MX2018000305A (ru) |
MY (1) | MY187033A (ru) |
PH (1) | PH12017502428A1 (ru) |
SG (1) | SG11201710734UA (ru) |
TW (2) | TWI787942B (ru) |
WO (1) | WO2016208695A1 (ru) |
ZA (1) | ZA201800359B (ru) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114409783A (zh) | 2015-06-24 | 2022-04-29 | Jcr制药股份有限公司 | 通过血脑屏障的抗人转铁蛋白受体抗体 |
US11130815B2 (en) | 2015-06-24 | 2021-09-28 | Jcr Pharmaceuticals Co., Ltd. | Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody |
BR112017024610A2 (pt) | 2015-06-24 | 2018-07-31 | F. Hoffmann-La Roche Ag | anticorpos para receptor antitransferrina com afinidade especificada |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
CN114031689A (zh) | 2015-10-02 | 2022-02-11 | 豪夫迈·罗氏有限公司 | 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法 |
SG11201804375WA (en) * | 2015-12-08 | 2018-06-28 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
US10759864B2 (en) * | 2016-12-26 | 2020-09-01 | Jcr Pharmaceuticals Co., Ltd. | Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier |
KR102471458B1 (ko) | 2016-12-28 | 2022-11-25 | 제이씨알 파마 가부시키가이샤 | 동결건조 제제 |
US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
HRP20221505T1 (hr) * | 2017-02-17 | 2023-02-17 | Denali Therapeutics Inc. | Proizvedeni polipeptidi za vezanje receptora transferina |
US10143187B2 (en) * | 2017-02-17 | 2018-12-04 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
SG10201913676QA (en) | 2017-04-01 | 2020-03-30 | Beijing hanmi pharm co ltd | Anti-pd-l1/anti-pd-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof |
EP3434692A1 (en) | 2017-07-24 | 2019-01-30 | Encefa | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
WO2019024979A1 (en) * | 2017-07-31 | 2019-02-07 | Institute For Research In Biomedicine | FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION |
WO2019049967A1 (ja) * | 2017-09-07 | 2019-03-14 | Jcrファーマ株式会社 | 水性医薬組成物 |
BR112020005271A2 (pt) | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
CA3088157A1 (en) * | 2018-01-10 | 2019-07-18 | Denali Therapeutics Inc. | Transferrin receptor-binding polypeptides and uses thereof |
IL276327B2 (en) * | 2018-02-05 | 2024-05-01 | Japan Chem Res | A method of administering a drug to a muscle |
US11753455B2 (en) | 2018-06-21 | 2023-09-12 | Novo Nordisk A/S | Compounds for treatment of obesity |
CN112512584A (zh) | 2018-07-27 | 2021-03-16 | 国立大学法人大阪大学 | 用于抑制衰老、预防、改善或治疗衰老相关疾病或症状、或者延长寿命的组合物 |
WO2020037150A2 (en) | 2018-08-16 | 2020-02-20 | Denali Therapeutics Inc. | Engineered bispecific proteins |
WO2020068058A1 (en) * | 2018-09-25 | 2020-04-02 | Academia Sinica | Anti-siglec antibody, pharmaceutical composition comprising the same, and uses thereof |
TW202029980A (zh) * | 2018-10-26 | 2020-08-16 | 美商免疫遺傳股份有限公司 | E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途 |
KR20200047937A (ko) * | 2018-10-26 | 2020-05-08 | 재단법인 목암생명과학연구소 | Ids를 포함하는 융합 단백질 및 이의 용도 |
SG11202105163UA (en) * | 2018-11-20 | 2021-06-29 | Perseus Proteomics Inc | Agent for inhibiting iron uptake into cells |
CN109486793B (zh) * | 2018-11-27 | 2020-08-04 | 江南大学 | 一种蔗糖水解酶突变体及其制备方法与应用 |
US20210403584A1 (en) * | 2019-01-08 | 2021-12-30 | Armagen, Inc. | Methods and compositions for increasing galactosidase beta-1 activity in the cns |
CN113474369A (zh) | 2019-01-09 | 2021-10-01 | 维克塔-霍洛斯公司 | 转铁蛋白受体结合分子、其偶联物和它们的用途 |
BR112021014574A2 (pt) | 2019-01-23 | 2021-10-05 | Encefa | Competidores cd31 e usos dos mesmos |
PE20230036A1 (es) | 2019-12-23 | 2023-01-10 | Denali Therapeutics Inc | Variantes de progranulina |
AU2021224412A1 (en) | 2020-02-22 | 2022-09-15 | Jcr Pharmaceuticals Co., Ltd. | Human transferrin receptor binding peptide |
CA3197506A1 (en) | 2020-10-14 | 2022-04-21 | Denali Therapeutics Inc. | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
US20240066149A1 (en) | 2021-01-12 | 2024-02-29 | Jcr Pharmaceuticals Co., Ltd. | Nucleic Acid Molecule Containing Incorporated Gene Encoding Fused Protein of Ligand and Protein Having Physiological Activity |
EP4298132A1 (en) * | 2021-02-23 | 2024-01-03 | Ichilov Tech Ltd. | Fusion proteins for treating cns diseases |
WO2022239817A1 (ja) * | 2021-05-12 | 2022-11-17 | Jcrファーマ株式会社 | ムコ多糖症i型の治療用医薬組成物 |
WO2023287238A1 (ko) * | 2021-07-15 | 2023-01-19 | 한양대학교 산학협력단 | 뇌혈관장벽 통과 효율이 향상된 항 인간 트랜스페린 수용체 항체, 및 이를 이용한 다중특이적 항체 및 약학 조성물 |
EP4373511A1 (en) | 2021-07-23 | 2024-05-29 | Denali Therapeutics Inc. | Methods for the treatment of hunter syndrome |
IL310898A (en) | 2021-08-19 | 2024-04-01 | Peptidream Inc | Human transfer receptor-peptide connector |
WO2023026994A1 (ja) * | 2021-08-21 | 2023-03-02 | 武田薬品工業株式会社 | ヒトトランスフェリンレセプター結合ペプチド-薬物コンジュゲート |
IL311025A (en) | 2021-08-24 | 2024-04-01 | Peptidream Inc | Human receptor binding antibody-peptides |
US11827702B2 (en) | 2021-09-01 | 2023-11-28 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
WO2023090409A1 (ja) * | 2021-11-19 | 2023-05-25 | Jcrファーマ株式会社 | ヒトトランスフェリン受容体親和性ペプチド |
AR128003A1 (es) * | 2021-12-17 | 2024-03-20 | Denali Therapeutics Inc | PROTEÍNAS DE FUSIÓN QUE COMPRENDEN ENZIMAS DE a-L-IDURONIDASA Y MÉTODOS PARA LAS MISMAS |
WO2023204202A1 (ja) * | 2022-04-19 | 2023-10-26 | Jcrファーマ株式会社 | マンノース-6-リン酸の数を減少させた糖蛋白質 |
WO2023207574A1 (zh) * | 2022-04-28 | 2023-11-02 | 领诺(上海)医药科技有限公司 | 一种穿越血脑屏障的重组hARSA |
WO2024010067A1 (ja) * | 2022-07-08 | 2024-01-11 | Jcrファーマ株式会社 | 中枢神経系疾患の治療のための、核酸分子、ベクター、組換え細胞及び薬剤 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
US5672683A (en) | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
US5527527A (en) * | 1989-09-07 | 1996-06-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
US5154924A (en) * | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
CA2123307A1 (en) | 1991-11-26 | 1993-06-10 | Phillip M. Friden | Process for the preparation of transferrin receptor specific antibody-neuro-pharmaceutical or diagnostic agent conjugates |
JPH06228199A (ja) | 1992-11-27 | 1994-08-16 | Takeda Chem Ind Ltd | 血液脳関門通過可能なペプチド結合体 |
EP0599303A3 (en) | 1992-11-27 | 1998-07-29 | Takeda Chemical Industries, Ltd. | Peptide conjugate |
US6472147B1 (en) | 1999-05-25 | 2002-10-29 | The Scripps Research Institute | Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries |
EP1197755A1 (en) * | 2000-10-11 | 2002-04-17 | Pepscan Systems B.V. | Identification of protein binding sites |
EP2277894A1 (en) * | 2000-10-27 | 2011-01-26 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic acids and proteins from streptococcus groups A & B |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7388079B2 (en) | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
US8053569B2 (en) | 2005-10-07 | 2011-11-08 | Armagen Technologies, Inc. | Nucleic acids encoding and methods of producing fusion proteins |
AR059089A1 (es) | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
CN101245107B (zh) * | 2007-02-14 | 2010-10-13 | 中国人民解放军军事医学科学院生物工程研究所 | 抗人转铁蛋白受体人源抗体及其应用 |
CA2607771A1 (en) * | 2007-11-01 | 2009-05-01 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence | Humanized anti-venezuelan equine encephalitis virus recombinant antibody |
US20100077498A1 (en) | 2008-09-11 | 2010-03-25 | Pardridge William M | Compositions and methods for blood-brain barrier delivery in the mouse |
EP2337795A2 (en) | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
CN102439040B (zh) * | 2009-04-16 | 2017-05-03 | 艾伯维生物医疗股份有限公司 | 抗TNF‑α抗体和其用途 |
PT2485761T (pt) * | 2009-10-09 | 2019-05-30 | Armagen Inc | Métodos e composições para aumentar a atividade da iduronato 2-sulfatase no snc |
JP5500944B2 (ja) | 2009-10-29 | 2014-05-21 | 三菱電機株式会社 | 加熱調理器 |
JP2012062312A (ja) | 2010-08-19 | 2012-03-29 | Yoshikatsu Eto | ハンター症候群の治療剤 |
ES2631356T3 (es) | 2010-11-30 | 2017-08-30 | F. Hoffmann-La Roche Ag | Anticuerpos anti-receptor de transferrina de baja afinidad y su uso para transferir scFv terapéuticos a través de la barrera hematoencefálica |
WO2012122396A1 (en) * | 2011-03-08 | 2012-09-13 | Baylor Research Institute | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
CA2828662A1 (en) | 2011-04-20 | 2012-10-26 | Roche Glycart Ag | Method and constructs for the ph dependent passage of the blood-brain-barrier |
EP2708560A4 (en) | 2011-05-09 | 2015-01-14 | Perseus Proteomics Inc | ANTIBODIES FOR THE SPECIFIC DETECTION OF TRANSFERRIN RECEPTORS |
TWI450727B (zh) | 2011-12-29 | 2014-09-01 | Ind Tech Res Inst | 抗人類輸鐵蛋白受體的單域抗體與其應用 |
EP3594239A1 (en) * | 2012-05-21 | 2020-01-15 | F. Hoffmann-La Roche AG | Methods for improving safety of blood-brain barrier transport |
RU2018129572A (ru) * | 2012-12-24 | 2018-10-12 | Эббви Инк. | Белки, связывающие рецептор пролактина, и их применение |
US9708406B2 (en) | 2013-05-20 | 2017-07-18 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
EP3003368A4 (en) * | 2013-05-24 | 2017-05-03 | Biogen MA Inc. | Anti-gpiib/iiia antibodies or uses thereof |
TW201536811A (zh) * | 2013-05-31 | 2015-10-01 | Biogen Idec Inc | 嵌合fvii-xten分子及其用途 |
US10906981B2 (en) | 2013-07-19 | 2021-02-02 | The Regents Of The University Of California | Compositions and methods related to structures that cross the blood brain barrier |
PE20160720A1 (es) | 2013-08-02 | 2016-07-28 | Hoffmann La Roche | Proteina de fusion terapeutica |
WO2015098989A1 (ja) | 2013-12-25 | 2015-07-02 | Jcrファーマ株式会社 | 血液脳関門を通過する新規抗トランスフェリン受容体抗体 |
MX2016008190A (es) | 2014-01-06 | 2016-10-21 | Hoffmann La Roche | Modulos de lanzadera de barrera cerebral sanguinea monovalente. |
CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
CN114409783A (zh) | 2015-06-24 | 2022-04-29 | Jcr制药股份有限公司 | 通过血脑屏障的抗人转铁蛋白受体抗体 |
US11130815B2 (en) | 2015-06-24 | 2021-09-28 | Jcr Pharmaceuticals Co., Ltd. | Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody |
MX2018000621A (es) | 2015-07-13 | 2018-05-11 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos. |
US10548986B2 (en) | 2016-03-02 | 2020-02-04 | Eisai R&D Management Co., Ltd. | Eribulin-based antibody-drug conjugates and methods of use |
KR102318480B1 (ko) | 2016-08-25 | 2021-10-28 | 제이씨알 파마 가부시키가이샤 | 항체 융합 단백질의 제조 방법 |
US10759864B2 (en) | 2016-12-26 | 2020-09-01 | Jcr Pharmaceuticals Co., Ltd. | Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier |
KR102471458B1 (ko) | 2016-12-28 | 2022-11-25 | 제이씨알 파마 가부시키가이샤 | 동결건조 제제 |
WO2019049967A1 (ja) | 2017-09-07 | 2019-03-14 | Jcrファーマ株式会社 | 水性医薬組成物 |
-
2016
- 2016-06-24 CN CN202210036310.3A patent/CN114409783A/zh active Pending
- 2016-06-24 SG SG11201710734UA patent/SG11201710734UA/en unknown
- 2016-06-24 CA CA2990785A patent/CA2990785A1/en active Pending
- 2016-06-24 AU AU2016283343A patent/AU2016283343B2/en active Active
- 2016-06-24 EA EA201890130A patent/EA039366B1/ru unknown
- 2016-06-24 TW TW110129238A patent/TWI787942B/zh active
- 2016-06-24 TW TW105119845A patent/TWI769982B/zh active
- 2016-06-24 BR BR112017027965A patent/BR112017027965A2/pt active Search and Examination
- 2016-06-24 US US15/739,200 patent/US11248045B2/en active Active
- 2016-06-24 CN CN201680036554.4A patent/CN107849555B/zh active Active
- 2016-06-24 MY MYPI2017705009A patent/MY187033A/en unknown
- 2016-06-24 EP EP16814464.0A patent/EP3315606A4/en active Pending
- 2016-06-24 MX MX2018000305A patent/MX2018000305A/es unknown
- 2016-06-24 WO PCT/JP2016/068738 patent/WO2016208695A1/ja active Application Filing
- 2016-06-24 KR KR1020187002182A patent/KR20180020277A/ko not_active Application Discontinuation
- 2016-06-24 JP JP2017524983A patent/JP6328851B2/ja active Active
-
2017
- 2017-12-21 IL IL256497A patent/IL256497B/en unknown
- 2017-12-22 PH PH12017502428A patent/PH12017502428A1/en unknown
- 2017-12-22 CL CL2017003351A patent/CL2017003351A1/es unknown
-
2018
- 2018-01-12 CO CONC2018/0000235A patent/CO2018000235A2/es unknown
- 2018-01-18 ZA ZA2018/00359A patent/ZA201800359B/en unknown
- 2018-04-12 HK HK18104803.9A patent/HK1245328A1/zh unknown
- 2018-04-18 JP JP2018080118A patent/JP6797148B2/ja active Active
- 2018-06-05 HK HK18107352.7A patent/HK1247962A1/zh unknown
- 2018-12-18 CL CL2018003680A patent/CL2018003680A1/es unknown
-
2019
- 2019-07-09 IL IL267960A patent/IL267960B/en unknown
-
2020
- 2020-11-17 JP JP2020191070A patent/JP7424961B2/ja active Active
-
2021
- 2021-11-19 US US17/530,587 patent/US20220064288A1/en active Pending
-
2022
- 2022-07-19 AU AU2022206724A patent/AU2022206724A1/en active Pending
- 2022-08-16 JP JP2022129602A patent/JP7411743B2/ja active Active
-
2023
- 2023-12-25 JP JP2023217901A patent/JP2024026498A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201890130A1 (ru) | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер | |
BR112019008854A2 (pt) | ligantes contendo peptídeo para conjugados de anticorpo-fármaco | |
PH12018500693A1 (en) | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | |
CY1119616T1 (el) | Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα | |
CY1125697T1 (el) | Σταθερες, υδατικες φαρμακοτεχνικες μορφες αντισωματων | |
EA201690848A1 (ru) | Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4 | |
PE20150892A1 (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco | |
EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
EA201890530A1 (ru) | Конъюгаты антитела к dll3 и лекарственного средства и способы их применения | |
EA201291158A1 (ru) | Комбинированные вакцины с синтетическими наноносителями | |
PE20150891A1 (es) | Anticuerpos anti-receptor de il-13 alfa 2 y conjugados de anticuerpo farmaco | |
EA201691023A1 (ru) | Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством | |
BR112013032717A2 (pt) | coagonistas do receptor de glucagon/glp-1 | |
BR112015011036A2 (pt) | derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais | |
MX340090B (es) | Analogos de spliceostatina. | |
EA201991526A1 (ru) | Конъюгаты антитела и лекарственного средства для разрушения гемопоэтических стволовых клеток | |
TR201908596T4 (tr) | Spiro-laktam NMDA reseptörü modülatörleri ve bunların kullanımları. | |
BR112018075651A2 (pt) | anticorpos anti-cd98 e conjugados anticorpo fármaco | |
EA201690388A1 (ru) | Новые производные унциаламицина, способы их синтеза и их применение в качестве противоопухолевых агентов | |
BR112014005935A2 (pt) | derivados de anilina, sua preparação e sua aplicação terapêutica | |
CL2018000131A1 (es) | Inmunoconjugados de il22 | |
EA202090542A1 (ru) | Высококонцентрированные лекарственные формы придопидина | |
MA52238A (fr) | Conjugués de médicament d'agents de liaison monoclonaux cmet, et utilisations associées | |
PH12016501039A1 (en) | Pharmaceutical dosage forms | |
UY34543A (es) | Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica. |